Malignant biliary strictures by bile duct cancer, gallbladder cancer, or pancreatic cancer
Conditions
Interventions
Endobiliary radiofrequency ablation by using a new catheter and biliary metallic stenting through ERCP
Sponsors
Digestive Disease Center and Research Institute, Department of Internal Medicine, SoonChunHyang University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) More than 19 in age 2) Extrahepatic malignant biliary stricture that was histophathologically or clinically confirmed 3)Unresectable or inoperable due to comorbidity or refusal of operation 4) More than 3 months of predictive survival
Exclusion criteria
Exclusion criteria: 1) Contraindications for ERCP 2) Uncontrolled coagulopathy: PT-INR > 1.5 (normal 0.85 - 1.25) or platelet count < 60,000/mm3 (normal 150,000 - 450,000/mm3) 3) Previously operation of bile duct 4) Impossible to access to the ampulla of Vater or failed selective biliary cannulation 5) Pregnant or breastfeeding women 6) Refusal to the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of early adverse events within 30 days after endobiliary radiofrequency such as hemobilia, bile duct perforation, pancreatitis, bleeding, cholangitis, perforation, or cholecystitis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Late adverse events after 30 days after endobiliary radiofrequency, stent patency of biliary metallic stent after endobiliary radiofrequency ablation, and patient survival after endobiliary radiofrequncy ablation. | — |
Countries
Asia(except Japan)
Contacts
Public ContactHyun Jong Choi
SoonChunHyang University School of Medicine Digestive Disease Center and Research Institute, Department of Internal Medicine
Outcome results
None listed